- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
First injectable for cellulite approved by FDA
The U.S. FDA has approved collagenase clostridium histolyticum-aaes (Qwo, Endo International), making it the first FDA-approved injectable treatment for moderate-to-severe cellulite in the buttocks in adult women.
The U.S. Food and Drug Administration (FDA) has approved collagenase clostridium histolyticum-aaes (Qwo, Endo International) for the treatment of moderate-to-severe cellulite in the buttocks in adult women, making it the first FDA-approved injectable cellulite treatment.
"[The] FDA approval of QWO is a key achievement in the continued execution of Endo's long-term strategy, especially as it relates to building our portfolio and capabilities for the future," says Blaise Coleman, president and CEO of Endo. "As Endo embarks on an exciting new journey into medical aesthetics, we look forward to bringing this innovative treatment to market through our Endo Aesthetics organization."
MORE: The current and emerging state of noninvasive body contouring
The injectable combines two collagenases, AUX-I and AUX-II, which are purified enzymes produced naturally by the clostridium histolyticum bacterium. Together, the enzymes degrade types 1 and 3 collagen by releasing the fibrous septae, which leads to an improvement in appearance and texture of the skin, according to the company.
"QWO could be a game-changer for many women with cellulite," says Anne Chapas, M.D., board-certified dermatologist at Union Square Laser Dermatology, New York City. "I am thrilled there will now be an FDA-approved injectable treatment option proven to address a root cause of cellulite. What is exciting about QWO is that it is a cutting-edge cellulite treatment, without the cutting."
The company expects the injectable to be available to aesthetic healthcare providers in the United States beginning in Spring 2021.
For more information about collagenase clostridium histolyticum-aaes, visit www.QWO.com.
References:
U.S. FDA Approves Qwo™ (collagenase clostridium histolyticum-aaes), the First Injectable Treatment for Cellulite. (2020, July 07). Retrieved July 07, 2020, from https://www.prnewswire.com/news-releases/us-fda-approves-qwo-collagenase-clostridium-histolyticum-aaes-the-first-injectable-treatment-for-cellulite-301088803.html
